First National Advisers’s United Therapeutics UTHR Stock Holding History

First National Advisers’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.68M	Sell	4,940 -383	-7%	-$216K	0.38%	70
2026 Q1	$3.16M	Sell	5,323 -946	-15%	-$471K	0.46%	57
2025 Q4	$3.05M	Sell	6,269 -2,064	-25%	-$961K	0.42%	65
2025 Q3	$3.49M	Buy	8,333 +251	+3%	+$84.4K	0.47%	58
2025 Q2	$2.32M	Buy	8,082 +296	+4%	+$88.5K	0.34%	94
2025 Q1	$2.4M	Buy	7,786 +3,073	+65%	+$1.05M	0.38%	83
2024 Q4	$1.66M	Buy	4,713 +372	+9%	+$137K	0.27%	103
2024 Q3	$1.56M	Buy	4,341 +333	+8%	+$112K	0.25%	111
2024 Q2	$1.28M	Buy	+4,008	New	+$1.06M	0.23%	119

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

First National Advisers's UTHR Position: Q2 2026 in Review

First National Advisers reduced its United Therapeutics (UTHR) stake by 7.2% in Q2 2026, selling an estimated $216K and leaving 4,940 shares worth $2.68M. The position accounts for 0.38% of the portfolio, ranked #70.

First National Advisers first reported a position in UTHR in Q2 2024 and has held it in 9 quarters since. The position peaked at $3.49M in Q3 2025. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

First National Advisers held 4,940 shares of United Therapeutics worth $2.68M as of Q2 2026.
First National Advisers sold 383 United Therapeutics shares in Q2 2026, an estimated $216K.
United Therapeutics made up 0.38% of First National Advisers's portfolio in Q2 2026, its #70 holding.
First National Advisers first reported a position in United Therapeutics in Q2 2024 and has held it in 9 quarters since.
First National Advisers's United Therapeutics position peaked at $3.49M in Q3 2025.
880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on First National Advisers's 13F filing for Q2 2026, filed 21 Jul 2026.